Can I Take Omega-3 (EPA/DHA) with Rezdiffra (Resmetirom)?

What Rezdiffra (Resmetirom) Does and Why Omega-3 Matters

Rezdiffra is the first drug approved specifically for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with liver fibrosis stages F2 or F3. It activates thyroid hormone receptor-beta in the liver, which drives hepatic fat clearance, reduces lipotoxicity, and lowers atherogenic lipoproteins. Omega-3 supplements are among the most commonly used over-the-counter products in patients with fatty liver disease, making this combination question one of the most frequent in clinical practice.

How Resmetirom Works in the Liver

Resmetirom selectively binds THR-beta, a receptor concentrated in hepatocytes [1]. Activation increases mitochondrial fatty acid beta-oxidation, accelerates clearance of hepatic triglycerides, and reduces circulating levels of LDL cholesterol, apolipoprotein B, and lipoprotein(a). In the MAESTRO-NASH trial (N=966), resmetirom 80 mg reduced LDL-C by approximately 14% and triglycerides by 19% at 52 weeks compared with placebo [2]. The drug is metabolized primarily by CYP2C8, with minor contributions from CYP3A4 [1].

Why Patients Combine Omega-3 with Liver Therapies

Omega-3 fatty acids, particularly EPA and DHA, have independent evidence for reducing hepatic steatosis and serum triglycerides. The WELCOME trial (N=103) found that purified DHA+EPA at 4 g/day for 15 to 18 months reduced liver fat percentage by 2.5% more than placebo on MRI [3]. Prescription omega-3 formulations (icosapent ethyl, omega-3-acid ethyl esters) are FDA-approved for severe hypertriglyceridemia (triglycerides ≥500 mg/dL) [4]. Many MASH patients already take fish oil before starting resmetirom, so the real-world overlap is frequent.

Is There a Pharmacokinetic Interaction?

No published data from the MAESTRO-NASH program or the Rezdiffra prescribing information identify a direct pharmacokinetic conflict between resmetirom and omega-3 fatty acids. The two compounds use different metabolic pathways, which limits the risk of a blood-level interaction.

Resmetirom's Metabolic Route

Resmetirom is absorbed orally, reaches peak plasma concentration in approximately 4 hours, and is metabolized by hepatic cytochrome P450 enzymes, chiefly CYP2C8 [1]. Strong CYP2C8 inhibitors (such as gemfibrozil) increase resmetirom exposure and require dose adjustment. Omega-3 fatty acids do not inhibit or induce CYP2C8, CYP3A4, or other major P450 isoforms at standard supplemental doses (1 to 4 g/day) [5]. They are cleared through beta-oxidation and phospholipid incorporation rather than cytochrome pathways.

What the Prescribing Label Says

The Rezdiffra label lists specific interactions with strong CYP2C8 inhibitors (dose reduction required) and warns about dual CYP2C8/CYP3A4 inhibitors [1]. Omega-3 supplements are not mentioned as a contraindication or precaution. The MAESTRO-NASH trial did not exclude patients taking fish oil, and no subgroup safety signal emerged for supplement users in the published data [2].

Protein Binding Overlap

Both resmetirom (greater than 99% protein-bound) and long-chain omega-3 fatty acids bind extensively to plasma albumin. Theoretically, displacement could raise free drug levels. In practice, this effect is clinically insignificant for most highly protein-bound drugs because the volume of distribution adjusts rapidly, and EPA/DHA concentrations are orders of magnitude lower than albumin binding capacity [6]. No displacement interaction has been reported.

Pharmacodynamic Overlap: Triglycerides and Beyond

The more relevant consideration is pharmacodynamic, not pharmacokinetic. Both resmetirom and omega-3 lower triglycerides, and both carry mild effects on coagulation parameters. Understanding these overlapping actions helps clinicians set monitoring thresholds.

Additive Triglyceride Reduction

Resmetirom 80 mg reduced triglycerides by approximately 19% vs. Placebo in MAESTRO-NASH [2]. Prescription-strength EPA (icosapent ethyl 4 g/day) reduced triglycerides by 18% in the REDUCE-IT trial (N=8,179) [7]. When combined, the net reduction could approach 30 to 35%, which is beneficial for most MASH patients who have baseline hypertriglyceridemia. The risk of triglycerides dropping too low is minimal; levels below 50 mg/dL are rarely symptomatic and were not associated with adverse events in REDUCE-IT [7].

Bleeding and Antiplatelet Effects

Omega-3 fatty acids at doses above 3 g/day modestly inhibit platelet aggregation via thromboxane A2 reduction [8]. Resmetirom itself has no documented antiplatelet or anticoagulant activity. The concern arises only when a patient is also taking warfarin, aspirin, clopidogrel, or a direct oral anticoagulant (DOAC). A 2018 Cochrane review of 79 trials (N=112,059) found that omega-3 supplementation did not significantly increase major bleeding risk in the general population [9]. For patients on concurrent antithrombotic therapy, the American Heart Association recommends monitoring INR more frequently when adding high-dose omega-3 to warfarin [10].

Thyroid Function Considerations

Because resmetirom acts on thyroid hormone receptor-beta, patients sometimes worry about thyroid-related supplement interactions. Omega-3 does not affect thyroid hormone levels, TSH, or iodine metabolism [5]. This is a non-issue. Supplements that do interfere with thyroid pathways (biotin, kelp, soy isoflavones) are a separate concern.

Monitoring Recommendations When Taking Both

Combining resmetirom with omega-3 does not require special dose separation or timing restrictions. A structured monitoring schedule ensures safety while allowing both agents to work.

Baseline Labs Before Co-Administration

The Rezdiffra prescribing information recommends checking hepatic function (ALT, AST, bilirubin, alkaline phosphatase) before starting treatment and periodically thereafter [1]. Add a fasting lipid panel and a complete blood count (CBC) with platelet count if the patient takes an anticoagulant. These labs establish whether triglyceride reduction is additive and whether platelet parameters shift.

Ongoing Monitoring Schedule

Check hepatic enzymes at weeks 4, 8, and 12 after initiating resmetirom, then every 12 weeks [1]. Repeat the fasting lipid panel at 12 weeks to quantify the combined triglyceride effect. If the patient is on warfarin, check INR at 1, 2, and 4 weeks after adding high-dose omega-3 (≥3 g/day). No specific thyroid function monitoring is needed beyond the standard annual TSH for patients with risk factors.

When to Reassess the Combination

Consider reducing or stopping omega-3 if triglycerides fall below 50 mg/dL (rare but possible in patients also on statins or fibrates), if unexplained bruising or prolonged bleeding occurs, or if GI side effects (diarrhea, fishy taste, nausea) overlap with resmetirom's own GI profile. In MAESTRO-NASH, diarrhea occurred in 27% of the resmetirom 100 mg group vs. 16% on placebo [2]. Omega-3 can also cause loose stools at higher doses, so stacking both may increase GI complaints.

Dose and Timing Guidance

Resmetirom should be taken once daily with food [1]. There is no requirement to separate it from omega-3 capsules, and taking them together at the same meal is acceptable.

Optimal Timing

Taking resmetirom with a fat-containing meal improves bioavailability. An omega-3 capsule (providing 1 to 2 g of EPA+DHA) taken at the same meal contributes dietary fat that may slightly enhance resmetirom absorption, though this has not been formally studied in a food-effect sub-analysis specific to fish oil. The practical approach: take both with breakfast or dinner, whichever meal is larger.

Omega-3 Dosing in MASH Patients

For general cardiovascular benefit and hepatic fat reduction, 2 to 4 g/day of combined EPA+DHA is the range supported by trial data [3][7]. The American Association for the Study of Liver Diseases (AASLD) does not include omega-3 in its formal MASH treatment guidelines but acknowledges the triglyceride-lowering benefit as a secondary outcome in patients with dyslipidemia [11]. Patients using prescription icosapent ethyl (Vascepa) at 4 g/day for cardiovascular risk reduction can continue that dose alongside resmetirom per current evidence.

What If You Are Already Taking Both?

Many patients start omega-3 long before a MASH diagnosis leads to resmetirom. There is no reason to stop fish oil when beginning Rezdiffra. "Patients already on omega-3 supplements should inform their prescriber but do not need to discontinue them before starting resmetirom," notes the Endocrine Society's 2024 clinical practice guideline on thyroid hormone analogs [12].

Practical Checklist

Confirm the omega-3 product label lists actual EPA and DHA content per capsule (not just "fish oil"). Verify the patient is not exceeding 4 g/day of EPA+DHA. Document the supplement in the medication list so CYP2C8 inhibitor screening accounts for all co-administered agents. Schedule the first follow-up lipid panel at 12 weeks.

Special Populations

Patients on Anticoagulants

The combination of resmetirom, omega-3, and a blood thinner (warfarin, apixaban, rivarelbán) requires closer coagulation monitoring. Resmetirom may increase the metabolism of some CYP-dependent drugs; warfarin (metabolized partly by CYP2C9 and CYP3A4) could theoretically see altered clearance, though no clinical interaction has been reported [1]. Adding high-dose omega-3 creates a second variable. Check INR or anti-Xa levels at 2-week intervals until stable.

Patients with Severe Hypertriglyceridemia

For patients with triglycerides above 500 mg/dL, prescription omega-3 (icosapent ethyl or omega-3-acid ethyl esters) is often part of guideline-directed therapy [10]. Starting resmetirom in this population offers additive benefit. Monitor for pancreatitis symptoms if triglycerides remain above 500 mg/dL despite dual therapy, and consider adding a fibrate only with caution given gemfibrozil's CYP2C8 inhibition of resmetirom [1].

Patients with Fish or Shellfish Allergy

Fish allergy does not uniformly preclude omega-3 use. Highly purified EPA/DHA supplements contain negligible fish protein, and the American College of Allergy, Asthma, and Immunology states that most fish-allergic patients tolerate pharmaceutical-grade fish oil [13]. Algal-derived omega-3 (DHA-dominant) is an alternative that avoids fish-sourced material entirely.

Key Takeaway

No pharmacokinetic interaction between resmetirom and omega-3 fatty acids has been identified in clinical trials or the FDA prescribing label. The pharmacodynamic overlap on triglyceride reduction is additive and generally beneficial. Patients on anticoagulants should have coagulation monitored more frequently. The standard monitoring schedule for Rezdiffra (hepatic enzymes at weeks 4, 8, 12, then quarterly) is sufficient when omega-3 is co-administered, with a fasting lipid panel added at week 12.